Promoting Excellence : Commonly Used Drugs for Symptoms of Patients with Chronic Kidney Disease

Renal Palliative Care Initiative: Commonly Used Drugs for Symptoms of Patients with Chronic Kidney Disease

This chart references the commonly prescribed drugs used to treat the symptoms accompanying end stage renal disease.

Clinical Care Tools - Symptom Management

Renal Palliative Care Initiative
Baystate Medical Center
759 Chestnut Street S2669
Springfield, MA 01199

Michael Germain, M.D.
[email protected]

How the grantee used this instrument:
This protocol was made available at the clinics and renal unit nursing stations.

esrd, end stage renal disease, dialysis, kidney disease, symptom assessment, medications

To use this tool:
You may print and copy this tool for your own use from this site. Please credit source.


  1. Altamura AC, Moro AR, Percudani M. "Clinical pharmacokinetics of fluoxetine." Clinical Pharmacokin, 1994;26:201-214.
  2. Anderson RJ, Gambertogolio JG, Schrier RW. "Clinical Use of Drugs in Renal Railure." Charles C Thomas, Springfield, IL. 1976
  3. Aronoff GR, Berns JS, Brier ME, Gloper TA, Morrison G, Singer I, Swan SK, Bennett WM. "Drug Prescribing in Renal Failure Dosing Guidelines for Adults," Fouth Edition. 1999: American College of Physicians - American Society of Internal Medicine, ISBN 0-943126-76-2.
  4. Borison RL. "Amantadine-induced psychosis in a geriatric patient with renal disease." American Journal of Psychiatry, 1979;136:111-112.
  5. Brater DC. "Drug Dosing in Renal Failure in Therapy in Nephrology and Hypertension," A companion to Brenner and Rector's THE KIDNEY, 641-653.
  6. Davies G, Kingswood C, Street M. "Pharmacokinetics of opioids in renal dysfunction." Clinical Pharmacokinet, 1996;31:410-422.
  7. Dheenan S, Venketesan J, Grubb BP, Henrich WL. "Effect of sertraline hydrochloride on dialysis hypotension." American Journal of Kidney Diseases, 1998;31:624-630.
  8. Facca A, Sanchez-Ramos J: "High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskenisias (letter)." Movement Disorders, 1996;11:327-329.
  9. Garzone PD, Kroboth PD. "Pharmacokinetics of the newer Benzodiazepines." Clinical Pharmacokinet, 1994:16:337-364.
  10. Hoppmann RA, Peden JG, Ober SK. "Central nervous system side effects of non-steroidal anti-inflammatory drugs." Archives of Internal Medicine, 1991;151:1309-1313.
  11. Inturrisi CE. "Disposition of narcotics in patients with renal disease." American Journal of Medicine, 1977;62:528-529.
    Lam YWF, Banerji S, Hatfield C, Talbert RL. "Principles of drug administration in renal insufficiency." Clinical Pharmacokinet, 1997;32:30-57.
  12. Laurijssens BE, Greenblatt DJ. "Pharmacokinetic-pharmacodynamic relationships for benzodiazepines." Clinical Pharmacokinet, 1996;30:52-76.
  13. Levy NB. "Psychiopharmacology in patients with renal failure." International Journal of Psychiatry in Medicine, 1990;20:325-334.
  14. Ochs HR, Greenblatt DJ, Labedzki L, Smith RB. "Alprazolam kinetics in patients with renal insufficiency." Journal of Clinical Psychopharmacol, 1986;6:292-294.
  15. Olyaei AJ, deMattos AM, Bennet WM. "Prescribing drugs in Renal Disease in Management of the patient with renal failure." 2606 - 2653.
  16. Preskorn SH. "Clinically relevant pharmacology of selective serotonin reuptake inhibitors." Clinical Pharmacokinet, 1997;32 (S1):1-21.
  17. Product Information: Ambien , zolpidem. G.D.Searle and Company, Skokie, IL, 1999.
  18. Product Information: Halcion , triazolam. UpJohn Laboratories, Kalamazoo, MI, 1994.
  19. Product Information: Poxicodone , oxycodone. Roxane Laboratories, Innc. Columbus, OH (PI revised 8/2000)
  20. Product Information: Sonata , zaleplon. Wyeth Laboratories, Philadelphia, PA, 1999.
  21. Product Information: Stelazine , trifluoperazine SmithKline & French, Philadelphia, PA 1995.
  22. Product Information: Talacen , pentazocine and acetaminophen. Sanofi-Synthelabo Inc, New York, NY, 1999.
  23. Product Information: Thorazine , chlorpromazine. SmithKline Beecham Pharmaceuticals, Philadelphia, PA (PI revised 4/99).
  24. Product Information: Zyprexa , olanzapine. Eli Lilly and Company, Indianapolis, IN (PI revised 10/2000).
  25. Rubin A, Lemberger L, Dhahir P: "Physiologic disposition of pergolide." Journal of Clinical Pharmacology, 1981;30:258-265.
  26. Sandoz M, Vandel S, Vandel B, Bonin B, Hory B, et al. Metabolism of amitriptyline in patients with chronic renal failure. European Journal of Clinical Pharmacology, 1984:26:227-232.
  27. Schmith VD, Piraino B, Smith RB, Kroboth PD. "Alprazolam in end stage renal disease:" Journal of Clinical Pharmacology, 1991;31:571-579.
  28. Schwenk MH, Verga MA, Wagner JD. "Hemodialyzability of sertraline." Clinical Nephrology, 1995;44:121-124.
  29. Wad N, Guenat C, Kramer G. "Carbamazepine: detection of another metabolite in serum, 9 hydroxymethyl-10-carbamoyl acridan." Theraputic Drug Monitor, 1997;19:314-317
  30. Wagner BKJ, O'Hara DA. "Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients." Clinical Pharmacokinet, 1997;33:426-453.
  31. Wong MO, Eldon MA, Keane WF, Turck D Bockbrader HN, et al. "Disposition of gapapentin in anuric subjects on hemodialysis." Journal of Clinical Pharmacology, 1995;35:622-626.
  32. Wood KA, Harris MJ, Morreale A, Rizos AL. "Drug-induced psychosis and depression in the elderly." Psychology Clinics of North America 1988;11:167193
  33. Bateman DN, "Clinical pharmacokinetics of metoclopramide." Clinical Pharmacokinet, 1983:8:523-9

To view this tool:
Left click on the download link to view the PDF document in your Web browser. Right-click on the download link to save the document to your computer.
pdf PDF 265 KB / 2 pages (Viewing PDF files requires downloading and installation of the free Adobe Acrobat Reader.)

Posted April 2004

Baystate Medical Center overview page

# BMC16, type:symptom_management

Promoting Excellence in End-of-Life Care was a national program of the Robert Wood Johnson Foundation dedicated to long-term changes in health care institutions to substantially improve care for dying people and their families. Visit for more resources.

Promoting Excellence logo and link to home page